论文部分内容阅读
目的 探讨表皮生长因子酪氨酸激酶抑制剂 吉非替尼对晚期非小细胞肺癌 (NSCLC)的治疗效果。方法 对 66例应用Iressa( 250mg/d)治疗的晚期NSCLC患者生活质量、生存期等临床资料,采用Logistic回归分析、χ2 检验、t检验的方法进行统计学分析。生活质量评估依据欧洲癌症研究和治疗组织QLQ-C30和QLQ-LC13问卷中文版进行。结果 本组患者用Iressa治疗的有效率为33% (22 /66),疾病控制率(有效+稳定 )为 70% (46 /66)。患者生活质量及相关临床症状QLQ-C30评分中各功能状态和综合生活质量评分的均值显著增加,改善率为 91% ~100%;QLQ-LC13评分中各项疾病相关症状评分的均值显著降低,改善率为 73% ~100%。药物的不良反应主要为Ⅰ级或Ⅱ级皮疹和腹泻,经对症处理可缓解。结论 吉非替尼用于晚期NSCLC治疗疗效确切,同时可改善患者的相关症状、提高生活质量。
Objective To investigate the therapeutic effect of epidermal growth factor tyrosine kinase inhibitor gefitinib on advanced non-small cell lung cancer (NSCLC). Methods The clinical data of 66 NSCLC patients treated with Iressa (250mg / d) were analyzed by Logistic regression analysis, χ2 test and t test. The quality of life assessment was based on the Chinese version of the QLQ-C30 and QLQ-LC13 questionnaires from the European Organization for Research and Treatment of Cancer. Results The effective rate of Iressa treatment was 33% (22/66) and the disease control rate (effective + stable) was 70% (46/66). The QLQ-C30 scores of patients with quality of life and all clinical symptoms and comprehensive quality of life scores were significantly improved, the improvement rate was 91% to 100%; QLQ-LC13 score of the disease-related symptom scores were significantly lower mean, Improvement rate of 73% to 100%. Adverse drug reactions mainly grade Ⅰ or Ⅱ rash and diarrhea, symptomatic treatment can be alleviated. Conclusion Gefitinib for the treatment of advanced NSCLC exact effect, while improving the patient’s symptoms and improve quality of life.